FDA warns of increased risks of asthma drug Xolair – AAP News (subscription)


GlobalPost

FDA warns of increased risks of asthma drug Xolair
AAP News (subscription)
Patients receiving the asthma medication Xolair (omalizumab) may have a slightly higher risk of serious adverse events affecting the cardiovascular and cerebrovascular systems, according to a review by the Food and Drug Administration (FDA). In
FDA: Asthma Drug May Increase Risk of CV, Cerebrovascular EventsMonthly Prescribing Reference

all 15 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.